News Gist .News

Articles | Politics | Finance | Stocks | Crypto | AI | Technology | Science | Gaming | PC Hardware | Laptops | Smartphones | Archive

Cassava Sciences Reports Financial Results and Business Update Period.

Cassava Sciences, Inc. reported financial results for the year ended December 31, 2024, with a net loss of $24.3 million, or $0.53 per share (basic), compared to $97.2 million in 2023. The company's cash and cash equivalents were $128.6 million at the end of 2024, with no debt, indicating improved financial management. Cassava Sciences is preparing to report the topline results of its Phase 3 study REFOCUS-ALZ, which will inform its next steps for simufilam in Alzheimer's disease.

See Also

Avecho Biotechnology Faces Financial Challenges in FY 2024 Δ1.74

Avecho Biotechnology reported a loss of AU$0.001 per share for its full year 2024 earnings, a significant improvement from the previous year's loss of AU$0.002 per share. The company's revenue increased by 139% to AU$1.13m, driven by growing demand for its products. Despite this positive trend, Avecho Biotechnology still faces financial challenges.

Asana (ASAN) Reports Q4: Everything You Need To Know Ahead Of Earnings Δ1.74

Asana is set to release its Q4 earnings report, with analysts predicting a revenue increase of 10% year-on-year to $188.2 million, although this marks a slowdown from the previous year's growth. The company has consistently outperformed revenue estimates, adding 661 new enterprise customers last quarter, which reflects its robust market presence. Comparisons with peers like Atlassian and Monday.com suggest a competitive landscape, as these companies have reported strong growth figures, potentially influencing market expectations for Asana.

Asana (Asan) Reports Q4: Everything You Need to Know Ahead of Earnings Δ1.73

Asana reported strong quarterly earnings, beating analysts' revenue expectations by 1.7% with revenues of $183.9 million, up 10.4% year on year. The company's solid performance was driven by a significant increase in enterprise customers paying more than $5,000 annually, reaching a total of 23,609. Asana has consistently exceeded analysts' expectations, beating revenue estimates every single time over the past two years.

ASTEEL Group Berhad Loses Ground: Financial Performance Takes a Hit Δ1.73

ASTEEL Group Berhad's Full Year 2024 Earnings report reveals a significant decline in revenue, with a 2.1% decrease from the previous year. The company also saw a notable narrowing of its net loss, improving by 64% compared to FY 2023. Despite this, the share price has taken a hit, dropping 14% over the past week.

Amphastar Pharmaceuticals Full Year 2024 Earnings: Eps Misses Expectations Δ1.73

Amphastar Pharmaceuticals' full-year 2024 earnings per share (EPS) missed analyst estimates by 7.4%, despite revenue growth of 14% from the previous year. The company's net income rose 16% to US$159.5m, with a profit margin of 22%. Amphastar's shares have declined 9.1% from a week ago.

Mesiniaga Berhad's Financial Woes: A Story of Declining Revenue and Rising Losses. Δ1.72

Mesiniaga Berhad, a Malaysian conglomerate, has reported a significant decline in revenue and net loss for the full year 2024, with a loss per share of RM0.056 compared to a profit of RM0.065 in the previous year. The company's revenue has decreased by 31% from FY 2023, while its net loss has more than doubled. The decline in financial performance raises concerns about the company's ability to recover and regain profitability.

Akzo Nobel N.V. Misses EPS by 12% Δ1.72

It's been a good week for Akzo Nobel N.V. shareholders, because the company has just released its latest full-year results, and the shares gained 2.5% to €59.52. Revenues were in line with forecasts, at €11b, although statutory earnings per share came in 12% below what the analysts expected, at €3.17 per share. The company's disappointing EPS miss may have been due to various factors such as higher raw material costs or increased competition.

Aimflex Berhad Full Year 2024 Earnings: EPS: RM0.006 (vs RM0.006 in FY 2023) Δ1.72

Aimflex Berhad's full year 2024 earnings report reveals a slight contraction in revenue and net income, with profit margins remaining relatively stable at 10%. The company's shares have taken a hit, falling 4% from the previous week, amidst concerns over its business performance. These results may be attributed to various factors, including market conditions, operational challenges, or strategic decisions.

ModivCare Full Year 2024 Earnings: EPS Misses Expectations Δ1.72

ModivCare's full year 2024 earnings missed analyst estimates by a significant margin, with the company reporting a net loss of US$201.3m, narrower than the previous year's loss of US$214.9m. Revenue grew 1.3% to US$2.79b, driven primarily by its NEMT segment, but the impact on earnings was substantial due to high cost of sales. The company's shares have declined 17% from a week ago.

Willowglen MSC Berhad Faces Financial Struggles in Full Year 2024 Earnings Report Δ1.72

Willowglen MSC Berhad reported a significant decline in earnings, with a loss of RM0.039 per share, down from a profit of RM0.021 in the previous year. The revenue also declined by 1.6% to RM205.9m. Despite this, the company's financial performance remains under scrutiny as investors and analysts assess its prospects for long-term growth.

Resimac Group Faces Revenue Challenges Ahead Δ1.72

Resimac Group's first half 2025 results show a decline in revenue and net income, with earnings per share (EPS) decreasing to AU$0.034 compared to AU$0.051 in the same period last year. The company's profit margin also decreased due to lower revenue, which may be attributed to a challenging Australian diversified financial industry. Despite this, Resimac Group forecasts an average revenue growth rate of 37% per annum for the next three years.

Osteopore's Full Year 2024 Earnings: A Slight Improvement Δ1.72

Osteopore reported a narrower net loss of AU$3.24m, a 33% reduction from the previous year, with revenue increasing by 27% to AU$2.81m. The company's shares are down 3.6% from a week ago, highlighting the risks associated with investing in Osteopore. Despite this, the improved financial performance suggests that the company is taking steps towards reducing its losses.

BCM Alliance Berhad Faces Financial Struggles as Revenue Grows Slowly Δ1.71

BCM Alliance Berhad's full-year 2024 earnings show a modest revenue increase of 2.6% from the previous year, with the company reporting a net loss of RM9.04 million, a decline of 79% from FY 2023. The loss per share is also reduced to RM0.004, an improvement from the RM0.021 loss in FY 2023. Despite this slight improvement, concerns remain over the company's financial health and future prospects.

Aurinia Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimate Δ1.71

Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) annual results exceeded expectations, with a statutory profit of US$0.04 per share, 54% above forecasts. The company's revenue growth is expected to slow down substantially, with analysts forecasting 10.0% growth on an annualized basis for the end of 2025. This is significantly lower than the historical growth rate of 47% over the past five years and the industry average of 20% per year.

Star Media Group Berhad Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next Δ1.71

Star Media Group Berhad has reported a full-year profit of RM0.092 per share, significantly exceeding analysts' expectations and reflecting a strong performance despite revenues aligning closely with forecasts. Looking ahead, analysts predict a decline in earnings per share by 83% to RM0.016 for 2025, indicating a cautious outlook even as they maintain a price target of RM0.42 for the stock. The consensus among analysts suggests a stable yet challenging environment for Star Media Group, with forecasts that appear to show confidence in the company’s fundamentals despite anticipated revenue shrinkage.

Zai Lab Limited (NASDAQ:ZLAB) Just Released Its Annual Results And Analysts Are Updating Their Estim Δ1.71

Investors in Zai Lab Limited (NASDAQ:ZLAB) had a good week, as its shares rose 2.5% to close at US$34.64 following the release of its annual results. Revenue hit US$399m in line with forecasts, although the company reported a statutory loss per share of US$2.60 that was somewhat smaller than the analysts expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of.

South Plains Financial Full Year 2024 Earnings: Beats Expectations Δ1.71

South Plains Financial's full-year 2024 earnings exceeded analyst expectations, with revenue decreasing by 9.5% and net income down 21%. The company's profit margin declined to 26%, driven by lower revenue, while its EPS grew by 11% above estimates. Revenue is forecast to grow 6.9% on average over the next two years.

Lovesac's Short-Term Slump Hidden in Long-Term Gains Δ1.71

The Lovesac Company's five-year share price growth may seem concerning with a 54% drop in the last quarter, but it pales in comparison to the impressive 176% return over this period. The company's transition from loss to profitability can be seen as an inflection point justifying strong share price gains. Fundamental metrics such as earnings and revenue growth trends are more important considerations than short-term market fluctuations.

Rubean AG (FRA:R1B) Approaches Breakeven Milestone Δ1.71

Rubean AG, a fintech company specializing in software point-of-sale solutions, is projected to reach breakeven in 2026 after reporting a loss of €1.6 million for the last financial year. Analysts predict that Rubean will need to achieve an average annual growth rate of 49% to turn a profit, highlighting investor confidence in the company's future despite its current cash-burning status. The absence of debt on Rubean's balance sheet reduces investment risk, offering a favorable outlook as it navigates its path to profitability.

Corbion Beats Expectations Despite Revenue Decline Δ1.71

Corbion, a Netherlands-based chemicals company, reported full-year 2024 earnings that beat analyst estimates, despite a decline in revenue of 11% compared to the previous year. The company's net income decreased by 37%, but its profit margin remained relatively stable at 3.6%. Looking ahead, Corbion forecasts growth of 5.1% per annum for the next three years.

Distribuidora Internacional De Alimentacion Sa (Xmad:dia) Reports Financial Turnaround Efforts Δ1.71

The company achieved significant progress in financial results, including a net profit of EUR28 million and positive cash flow generation. Distribuidora Internacional De Alimentacion SA successfully completed the turnaround of its business, resulting in two high-performing platforms in Spain and Argentina. The refinancing agreement extended debt maturity until 2029, providing a solid financial structure and increased liquidity by EUR92 million.

Medibank Private Limited Beats Analyst Forecasts, And Analysts Have Been Updating Their Predictions Again. Δ1.70

Medibank Private Limited has surprised analysts with its latest earnings report, delivering a statutory profit of AU$0.12 per share, 17% above expectations. The company's shares have surged 10% to AU$4.35 in the week since the results were announced, and the analysts have updated their forecasts, predicting revenues of AU$8.60b in 2025 and a 27% increase in statutory earnings per share. Despite some variation in analyst estimates, the overall consensus is that Medibank Private's growth prospects have improved.

South Bow Full Year 2024 Earnings: EPS Misses Expectations Δ1.70

South Bow reported a revenue increase to US$2.12 billion for the full year 2024, reflecting a 5.7% growth from the previous year. However, net income fell by 28% to US$316 million, resulting in a profit margin decrease from 22% to 15%, primarily due to rising expenses. The company's earnings per share (EPS) of US$1.52 missed analyst expectations by 15%, and future revenue growth is projected to remain flat, contrasting with the broader industry forecast.

Caq Holdings Full Year 2024 Earnings: Share Price Remains Stable Despite Profitable Loss Δ1.70

CAQ Holdings' Full Year 2024 Results Key Financial Results Net loss: AU$3.83m (loss widened by 22% from FY 2023). AU$0.005 loss per share (further deteriorated from AU$0.004 loss in FY 2023). The company's profitability may be impacted by the significant increase in operating expenses.

Seremban Engineering Berhad Second Quarter 2025 Earnings: EPS: RM0.004 (vs RM0.005 in 2Q 2024) Δ1.70

The conglomerate's second-quarter earnings report reveals a decline in revenue and net income, with significant drops of 40% and 18%, respectively. The company attributed the decrease to lower expenses, which contributed to an improvement in its profit margin from 0.8% to 1.1%. Despite this, Seremban Engineering Berhad's share price has remained relatively unchanged.